Clinical Trial Finder

Inclusion Criteria:

1. Participant must be 18 years of age or older at the time of signing the informed consent. 2. Participant has a histologically confirmed diagnosis of advanced/metastatic melanoma ore relapsed refractory metastatic non-small cell lung cancer (NSCLC). 3. Melanoma participant experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blocking antibody. If the tumor is BRAF V600 mutation-positive, the participant should also have received a BRAF inhibitor with or without a MEK inhibitor. Participants with non-small cell lung cancer should have relapsed or are refractory to approved systemic therapies (approved ICI-based regimen for all appropriate participants and/or an approved targeted therapy for known molecular abnormalities if applicable to their disease). 4. Participant is assessed as having at least one lesion (or aggregate lesions) suitable for OBX-115 generation. 5. After tumor tissue procurement, the participant will have at least one remaining measurable lesion, as defined by RECIST v1.1. 6. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of >6 months. 7. Participant has recovered from all prior anticancer treatment-related AEs to at least Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE]). 8. Participants must have completed post-operative recovery from any prior surgical procedures with wound healing and resolution of all surgical complications prior to planned tumor procurement surgery. 9. Both male and female (women of childbearing potential) participants agree to the follow protocol specified contraceptive and/or abstinence requirements. 10. Participant has protocol specified hematologic parameters for absolute neutrophil count (ANC) and platelet count. 11. Participant has adequate cardiac, liver, lung, and kidney organ function as specified in the protocol.

Exclusion Criteria:

1. Participant has melanoma of uveal origin. 2. Participant has a history of brain metastases or leptomeningeal disease, except patients with brain metastases that are up to 1.5cm in diameter that have been treated and are stable. 3. Participant has an active medical illness(es) that, in the opinion of the Investigator, would pose increased risks for study participation. 4. Participants with non-small cell lung cancer with refractory and clinically significant pleural effusions. 5. Participant has any form of primary or acquired immunodeficiency. 6. Participant has a history of hypersensitivity to any component of the study intervention. 7. Participant had another primary malignancy within the previous 3 years (with protocol specified exceptions). 8. Participant has a history of allogeneic organ transplant, allogeneic cell therapy, or genetically engineered cell therapy. Prior unegineered TIL cell therapy is allowed. 9. Participant requires systemic steroid therapy >10 mg/day of prednisone or equivalent. 10. Participant received a live or attenuated vaccination within 28 days prior to the start of lymphodepletion (LD). 11. Participant has evidence of positive infectious disease screening and/or any active uncontrolled viral, bacterial, or fungal disease requiring ongoing systemic treatment or identified during screening.

Primary Objective (Phase 1): • Assess the safety and tolerability of OBX-115 regimen. Primary Objective (Phase 2): • Evaluate preliminary efficacy of OBX-115 regimen as measured by the investigator using objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary (Phase 1): • Assess preliminary efficacy of OBX-115 regimen by evaluating ORR. Secondary (Phase 2): • Evaluate safety and tolerability of OBX 115 based on the collected AE data. Secondary (both Phase 1 and Phase 2):

• - Evaluate duration of response (DOR): To evaluate the duration from the time that criteria are met for CR or PR per RECIST v1.1 as assessed by the investigator until disease progression or death due to cancer.

• - Evaluate disease control rate (DCR): To evaluate the percentage of participants with a best overall confirmed response of CR or PR at any time plus stable disease (SD) for at least 4 weeks per RECIST v1.1 as assessed by the investigator.

• - Evaluate progression-free survival (PFS): To evaluate the time from the date of OBX-115 infusion until disease progression per RECIST v1.1 as assessed by the investigator or death due to any cause.

• - Evaluate overall survival (OS): To evaluate the time from the date of OBX-115 infusion to death due to any cause.

• - Evaluate feasibility of the manufacturing process: Evaluated as the proportion of OBX-115 products initiated for manufacturing that pass release criteria for infusion.

Arms

Experimental: Participants with advanced solid tumors

Participants will receive conditioning therapy prior to administration of OBX-115 regimen.

Interventions

Biological: - OBX-115

A tumor sample is obtained from each participant for autologous OBX-115 manufacture. After lymphodepletion including cyclophosphamide and fludarabine, participant will receive OBX-115 infusion, followed by a short course of acetazolamide.